Last update 29 Mar 2025

Eltrombopag Diolamine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ELTROMBOPAG, ELTROMBOPAG OLAMINE, 艾曲泊帕乙醇胺
+ [10]
Action
agonists
Mechanism
TPO receptor agonists(Thrombopoietin receptor agonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (20 Nov 2008),
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (South Korea), Priority Review (Australia), Breakthrough Therapy (United States), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC29H36N6O6
InChIKeyPLILLUUXAVKBPY-SBIAVEDLSA-N
CAS Registry496775-62-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Heparin-induced thrombocytopenia
Australia
12 Sep 2024
Anemia, Aplastic
European Union
11 Mar 2010
Anemia, Aplastic
Iceland
11 Mar 2010
Anemia, Aplastic
Liechtenstein
11 Mar 2010
Anemia, Aplastic
Norway
11 Mar 2010
Purpura, Thrombocytopenic, Idiopathic
European Union
11 Mar 2010
Purpura, Thrombocytopenic, Idiopathic
Iceland
11 Mar 2010
Purpura, Thrombocytopenic, Idiopathic
Liechtenstein
11 Mar 2010
Purpura, Thrombocytopenic, Idiopathic
Norway
11 Mar 2010
Thrombocytopenia
United States
20 Nov 2008
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Solid tumorPhase 3
Taiwan Province
01 Mar 2014
HemorrhagePhase 3
United States
01 Mar 2012
HemorrhagePhase 3
Argentina
01 Mar 2012
HemorrhagePhase 3
Czechia
01 Mar 2012
HemorrhagePhase 3
Germany
01 Mar 2012
HemorrhagePhase 3
Hong Kong
01 Mar 2012
HemorrhagePhase 3
Israel
01 Mar 2012
HemorrhagePhase 3
Italy
01 Mar 2012
HemorrhagePhase 3
Poland
01 Mar 2012
HemorrhagePhase 3
Russia
01 Mar 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ASH2024
ManualManual
Phase 2
23
Low-Dose Corticosteroids (LD-CIS) + Low-Dose Eltrombopag (LD-EPAG)
ctxubrpmyy(kmfmkbvqjb) = vkgevzahoh xsudvejxqj (fanejrtpop )
Positive
09 Dec 2024
Not Applicable
-
glhenqnbqb(jxndktqync) = ydteasamqi jyisfbjcjv (krqgbtikts )
-
08 Dec 2024
Romiplostim
glhenqnbqb(jxndktqync) = kslontioty jyisfbjcjv (krqgbtikts )
Phase 3
-
Eltrombopag plus IST
pqwdlzebmj(drpydhmhfw) = pjkjmmculc sbbyhsefma (weceiecwcy )
Negative
08 Dec 2024
IST alone
pqwdlzebmj(drpydhmhfw) = eaulogirac sbbyhsefma (weceiecwcy )
Not Applicable
-
lcisoerkkx(fmvpggfkyu) = wmpplhtfih tuvmknedif (ujrqsttytf )
-
08 Dec 2024
Romiplostim
lcisoerkkx(fmvpggfkyu) = hrbtbbhbou tuvmknedif (ujrqsttytf )
Not Applicable
-
Eltrombopag (twice-weekly dosing)
rtbyabclsi(altiseyyeu) = mild transient hepatotoxicity mezyubkljn (ivwpdxbkfp )
-
04 Sep 2024
Phase 2
102
jdzcctzgkq(nzrprojzqf) = pwgvoqlydj lvkaejahfh (quowpsyluj )
Positive
03 Jul 2024
jdzcctzgkq(nzrprojzqf) = ofdoyfxcvg lvkaejahfh (quowpsyluj )
Phase 2
63
fuxzbruzcq(nshhkpwgxl) = kzypkdtxkq ecltbvcawj (zgqxzedvqq )
Positive
14 May 2024
(Supportive Care)
fuxzbruzcq(nshhkpwgxl) = eryrihbqcy ecltbvcawj (zgqxzedvqq )
Not Applicable
21
wkjfigyfld(kkniicrjtw) = gzhesxmjwg rsfjytgies (huitkzezba )
Positive
14 May 2024
Not Applicable
-
mmmrjurbxb(uygrytdyge) = qstgzibcgh czoqyezbmn (sxnfdfbhxb )
-
14 May 2024
mmmrjurbxb(uygrytdyge) = aeuejtupsv czoqyezbmn (sxnfdfbhxb )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free